The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of a High-Throughput Screening (HTS) Platform for the discovery of medications to treat Alcohol Use Disorder (AUD). The current drug development process for Central Nervous System (CNS) medications is lengthy and costly, with a high failure rate. The goal is to develop a more efficient screening model that can test multiple candidate compounds and drug combinations using new compound discovery approaches such as Connectivity Maps and artificial intelligence (AI). The HTS platform should incorporate cell- and tissue-based models, including brain cells and organoids derived from induced pluripotent stem cells, as well as small vertebrate and invertebrate model organisms like zebrafish, fruit flies, and roundworms. The platform should be sensitive to alcohol and produce measurable changes within the model. The development of AI and the use of molecular networks within the brain could lead to the identification of new candidate compounds. The Phase I activities include the development or optimization of a screening platform, incorporation of AI, testing of compounds with known clinical profiles, and specifying evaluation metrics. Phase II activities involve benchmarking the system against existing data, testing additional compounds, and validating promising compounds in animal models. The commercialization potential of a validated HTS platform includes its value to pharmaceutical companies and researchers in discovering new compounds for AUD and other disorders. The platform could also be used to screen compounds for other medical and psychiatric disorders.